24 clinical trials matched your search for Bladder Cancer. You can click one of the clinical trials below for more information, or click the Search Again button to enter different search text.

Search Again
Condition Study Title Investigator
Bladder Cancer ADAPT-BLADDER: Modern Immunotherpy in BCG-Relapsing Urothelial Carcinoma of the Bladder Christopher Anderson, MD
Bladder Cancer Study of Gemcitabine and Docetaxel Treatment in Patients with Bladder Cancer (BRIDGE) Andrew Lenis, MD
Cancer Identification of Targets for Cancer Treatment Andrea Califano, PhD
Cancer Study of IDE196 in Patients with Solid Tumors Alexander Wei, MD
Cancer Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs) Brian Henick, MD
Cancer Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Catherine Shu, MD
Cancer Study of IMC-F106C Alone and in Combination With Checkpoint Inhibitors in Participants with Advanced Cancers Benjamin Izar, MD
Cancer Study of BAY 1895344 in Combination with Chemotherapy for Patients with Advanced Cancer Mark Stein, MD
Cancer Study of Financial Navigator Addressing Cancer-Related Financial Hardship in Cancer Patients and Their Spouses Dawn Hershman, MD
Cancer Study of RP-3500 in Combination with PARP Inhibitor for Patients with Advanced Cancer Benjamin Herzberg, MD
Cancer Study of IDE397 in Patients with Advanced Solid Tumors Benjamin Herzberg, MD
Cancer Study of CS5001 in Patients with Advanced Solid Tumors Hua-Jay Cherng, MD
Cancer Study of BT7480 in Patients with Advanced Cancer Mark Stein, MD
Cancer Study of ASP3082 in Patients with Advanced Cancer with a KRAS G12D Mutation Benjamin Herzberg, MD
Cancer Study of 68Ga-FAP-2286 and 177Lu-FAP-2286 in Patients with Advanced Cancer Ryan Moy, MD
Cancer Study of BLU-222 Alone or in Combination with Other Cancer Therapy for Patients with Advanced Cancer Brian Henick, MD
Cancer Study of LNS8801 Alone or in Combination with Pembrolizumab in Patients with Advanced Cancer Brian Henick, MD
Cancer Study of RMC-6291 in Patients with Advanced Solid Tumors Benjamin Herzberg, MD
Cancer Study of XL092 Alone or in Combination with Anticancer Therapy in Patients with Unresectable orMetastatic Solid Tumors Karie D. Runcie, MD
Cancer Study of MRT-2359 in Patients with Solid Tumors Benjamin Herzberg, MD
Cancer Study of RMC-6236 in Patients with Solid Tumors with a KRAS Mutation Benjamin Herzberg, MD
Cancer Study of NDI-101150 Alone or in Combination with Pembrolizumab in Patients with Solid Tumors Ryan Moy, MD
Cancer Study of XmAb808 in Combination with Pembrolizumab in Patients with Advanced Cancer Mark Stein, MD
Cancer Study of HRO761 Alone or in Combination with Tislelizumab or Irinotecan in Patients with Solid Tumors Edmond Chan, MD
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE